What The Aurum Institute does

The Aurum Institute is a South Africa-based non-profit health impact organization founded circa 2000 and headquartered in Johannesburg, with 1,001–5,000 employees and operations spanning 78 countries. Its core offering is organized into three service divisions: Clinical Research (basic science, multi-site clinical trials for drugs, vaccines, and regimens, supported by biorepository and clinical laboratory capabilities); Implementation Research (epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies); and Health Programmes (major development interventions, targeted projects, technical assistance, and infrastructure development). Therapeutic areas include Tuberculosis, HIV, COVID-19, Health Systems Strengthening, Market Access, and Antimicrobial Resistance, with impact metrics of 1.5 million people screened for TB, over 15 million tested for HIV, 412,702 COVID vaccines administered, and more than 13 million patient courses of rifapentine-based TB preventive treatments delivered across 78 countries.

The organization is funded primarily through grants and partnerships rather than commercial sales. Unitaid's US$52 million SUPREME initiative (March 2026), with CHAI and Amref, addresses maternal health across seven African countries, while IMPAACT4TB was a Unitaid-funded TB project managed by Aurum through its 2025 close-out. Geographic reach extends through country entities in Ghana, Mozambique, the USA (Aurum USA), and Brazil (Fundação Aurum), with affiliate brands IMPAACT4TB, INNOVA, Youth Health Africa, and GHI. Founder and CEO Gavin Churchyard leads the organization under a Board of Directors and Group Executive Management governance structure. Recent risk signals include referenced cuts to US government research grants affecting Aurum and peer organizations in the National BioData Consortium context.

The business model is non-commercial: Aurum does not sell products or APIs, operates no software platform, and does not disclose pricing. Revenue derives from restricted and unrestricted grants, donor funding, and institutional partnerships. Customer-facing work is delivered through governments, public health programmes, and international health organizations, positioning Aurum as an implementation and evidence-generation intermediary between global health funders and on-the-ground public health delivery in Africa.

Name

The Aurum Institute

Legal name

The Aurum Institute

Website

https://auruminstitute.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Aurum Institute is a South Africa-based non-profit health research and implementation organization founded circa 2000, delivering clinical trials, implementation research, and health programmes across 78 countries, primarily focused on tuberculosis, HIV, COVID-19, and health system strengthening in Africa.

Ownership category

akta.pro rank

Product category

Global Public Health Research and Implementation Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

akta.pro secondary industries

Tuberculosis & Mycobacterial Diseases (HLAKAGAH), Global Health Institutes & Programs (EDAHAGAM), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)

Keywords

• Clinical research services
• Global health programmes
• Tuberculosis prevention
• HIV testing treatment
• Health systems strengthening

Headquarters

HQ city

Johannesburg

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Marketing channels2 records

Core offering

The Aurum Institute is a nonprofit health impact organisation that conducts clinical and implementation research and delivers large-scale health programmes focused on tuberculosis, HIV, COVID-19, antimicrobial resistance, and health systems strengthening. It operates clinical research facilities including biorepositories and laboratories, runs multi-site clinical trials for drugs, vaccines, and regimens, and executes major development intervention programmes with technical assistance to governments across Africa and globally.

Product overview

The Aurum Institute is a health impact organization operating as a single unified offering rather than a platform-plus-modules architecture. Its core services consist of three interconnected divisions: Clinical Research (providing basic science, multi-site clinical trials, biorepository, and clinical laboratory services), Implementation Research (delivering epidemiology, geomapping, real-world evidence, and multi-site implementation studies), and Health Programmes (executing development interventions, targeted projects, technical assistance, and infrastructure development). These services are organized around therapeutic areas including Tuberculosis, HIV, COVID-19, Health Systems, Market Access, and Antimicrobial Resistance. The organization maintains global reach through affiliates IMPAACT4TB, INNOVA, and Youth Health Africa, with international operations in Ghana, Mozambique, USA, and Brazil through Fundação Aurum. Aurum is NOT a technology product company—it does not offer software products, APIs, AI-powered tools, or integrations.

Differentiator

Problem solved

Functional benefit

Brands

• IMPAACT4TB: A project focused on TB research and implementation for children and adolescents
• INNOVA
• Youth Health Africa

Products and services

• Clinical Research Division Provides basic science research, multi-site clinical trials for drugs, vaccines and regimens, biorepository, and clinical laboratory services for governments, donors, and research partners.
• Implementation Research Division Conducts epidemiology and geomapping, real-world evidence generation, and multi-site implementation studies for public health programmes and policy makers.
• Health Programmes Delivers major development intervention programmes, targeted intervention projects, technical assistance, and infrastructure development for governments and donor-funded health initiatives.
• Tuberculosis Prevention & Treatment Programme Comprehensive TB screening, testing, and rifapentine-based preventive treatment programme that has reached over 13 million patient courses across 78 countries.
• HIV Prevention & Treatment Programme HIV testing and treatment services integrated with TB programmes, with over 15 million people tested to date across Africa.
• COVID-19 Response Programme COVID-19 vaccination and pandemic response programme, including the administration of 412,702 COVID-19 vaccines to date.
• Antimicrobial Resistance (AMR) Programme Programme addressing antimicrobial resistance challenges through research and implementation activities.
• Health Systems Strengthening Service area covering quality improvement, system improvement, health information systems, and market shaping initiatives for government and donor partners.
• Market Access Programmes focused on improving access to health products and treatments across African and other low- and middle-income markets.
• IMPAACT4TB Unitaid-funded project managed by Aurum focused on TB prevention and treatment, particularly for children and adolescents.
• INNOVA Affiliate organisation of The Aurum Institute focused on health innovation and technology initiatives.
• Youth Health Africa Affiliate organisation of The Aurum Institute delivering youth-focused health programmes and employment initiatives in Africa.

Quantifiable outcome

• 1.5 million people screened for TB
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• CHAI (Clinton Health Access Initiative)coreStrategic or Co-development PartnerCollaborates with Aurum on the SUPREME initiative alongside Unitaid and Amref to tackle preeclampsia and anemia across seven African countries.
• AmrefcoreStrategic or Co-development PartnerPartners with Aurum on the SUPREME initiative to provide expertise alongside CHAI and Unitaid funding to address preeclampsia and anemia across seven African countries.
• IMPAACT4TBcoreStrategic or Co-development PartnerA Unitaid-funded project managed by Aurum that marked its global close-out at the Union World Conference on Lung Health 2025. The project worked on TB treatment and prevention.
• Youth Health AfricaminorStrategic or Co-development PartnerAffiliate organization focused on youth health initiatives in Africa.
• INNOVAminorStrategic or Co-development PartnerAffiliate organization of The Aurum Institute focused on health innovation.
• GHI (Global Health Impact)minorStrategic or Co-development PartnerAffiliate organization operating in South Africa.
• National BioData Consortium (NBDC)minorStrategic or Co-development PartnerCollaboration referenced in blockchain for genetic data sharing context. Organizations like Aurum and NBDC have faced severe cuts to US government research grants.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Partners in Health: Global nonprofit that pairs clinical research with health system strengthening and direct care delivery in low-resource settings. Closely comparable to Aurum's integrated research-plus-implementation model, particularly across HIV, TB, and maternal health in Africa and the Caribbean.
• KNCV Tuberculosis Foundation: Dutch-based TB-focused NGO with deep experience in TB prevention, treatment, and policy advocacy in low- and middle-income countries. Directly comparable to Aurum's TB franchise, including rifapentine-based preventive therapy rollouts and technical assistance to national TB programmes.
• Clinton Health Access Initiative (CHAI): Global health organization that works with governments to strengthen health systems and improve access to medicines for HIV, TB, malaria, and maternal health. Directly comparable as both a co-implementer on Aurum's SUPREME initiative and a peer in evidence-to-policy and market-shaping work.
• Infectious Diseases Institute (IDI): Uganda-based African clinical research and training institute with strong HIV and TB programmes, biorepository capacity, and implementation research expertise. Closely comparable to Aurum as a fellow African-headquartered research-to-implementation NGO.
• Elizabeth Glaser Pediatric AIDS Foundation (EGPAF): Global nonprofit focused on HIV prevention, treatment, and research, with substantial footprint across sub-Saharan Africa. Directly comparable to Aurum on HIV testing/treatment scale (15M+ HIV tests) and on integration with maternal and child health programming.

Broad incumbents

• FHI 360: Large international NGO combining implementation research, clinical trials, and health programme delivery across HIV, TB, and infectious disease in developing countries. Broader and more diversified than Aurum, but operates a similar research-to-implementation model with global reach.
• PATH: Global health innovation organization with significant work in vaccines, diagnostics, and infectious disease across low- and middle-income countries. Comparable to Aurum in its mix of clinical research, implementation, and market-shaping activities, though at substantially larger scale.

Regional players

• Wits Health Consortium: South African clinical research and health systems organization affiliated with the University of the Witwatersrand, with comparable HIV and TB trial and implementation activity. Functions as a domestic South African peer with overlapping funder base and disease focus.

Emerging players

• TB Alliance: Product Development Partnership developing and delivering improved TB regimens, including work on rifapentine-based preventive therapy that overlaps with Aurum's IMPAACT4TB franchise. Comparable as a TB-focused R&D and access organization, though more product-development oriented than Aurum.
• amfAR, The Foundation for AIDS Research: International nonprofit funding HIV/AIDS research and advocacy globally. Comparable to Aurum on the HIV research and policy translation dimension, though Aurum has a stronger implementation footprint than amfAR's primarily grant-making model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Auruminstitute
• YouTubeyoutube.com/channel/UCCkUO21eZeNd72MDr9kyaWw
• Facebookfacebook.com/theauruminstitute
• LinkedInlinkedin.com/company/the-aurum-institute
• Instagraminstagram.com/auruminstitute

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Aurum Institute